0009K0 (0009K0)
KRX SM KRX SM Primary Summary
0009K0 Chart
0009K0 (0009K0) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has 0009K0 ever had a stock split?
0009K0 Profile
| - Industry | - Sector | Mr. Nam-Gu Her Ph.D. CEO | KRX SM Exchange | - ISIN |
| South Korea Country | - Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Aimed Bio Inc. is a biotechnology company that focuses on developing innovative therapeutic solutions specifically for patients suffering from brain diseases. These include both neuro-oncological conditions, such as brain tumors, and various degenerative brain disorders. Founded in 2018 and headquartered in Seoul, South Korea, Aimed Bio Inc. employs a multidisciplinary approach to its research and development efforts. The company leverages a range of technologies and methodologies to enhance drug efficacy and penetration into the brain, aiming to provide effective treatments that address unmet medical needs in the realm of neurology.
Products and Services
- Antibody-Drug Conjugates (ADCs)
Aimed Bio Inc. specializes in the design and development of antibody-drug conjugates, which are engineered to deliver cytotoxic agents directly to cancerous cells in the brain. This targeted approach minimizes collateral damage to healthy tissues and enhances the therapeutic impact on malignancies.
- Blood-Brain Barrier Penetration
The company is actively developing strategies and technologies to improve the penetration of therapeutic agents across the blood-brain barrier (BBB), a significant challenge in treating brain diseases. This initiative aims to ensure that medications can effectively reach their targets within the central nervous system.
- Brain Immune Modulation
Aimed Bio Inc. is working on innovative methods for modulating the immune response in the brain. By targeting immune pathways, the company seeks to enhance the body’s natural defenses against neuro-oncological and degenerative diseases, providing a complementary approach to traditional therapies.
- Patient-Derived Models (PDC/PDX)
The use of patient-derived models, including Patient-Derived Cultures (PDC) and Patient-Derived Xenografts (PDX), allows Aimed Bio Inc. to study the biological characteristics of individual patients’ tumors and diseases. This personalized approach supports the development of tailored therapies that are more effective and with fewer side effects.
